Prof Thomas Voit, DMD expert, interview with Wilsons advisory, page-31

BTW: they are finally starting to communicate like a 'growth stock'.

Ahead of major anns like EMA P2B approvals and FDA orphan drug applications, don't be surprised if we receive some goodies from the lab to drive momentum.

This 'next steps' statement from may ann is very interesting - I'm expecting more data to be shared soon:
___________________________________

As ANP continues to prepare for a Phase IIb, the Company will look to gain a deeper understanding of the drug's effects. This activity is likely to include further laboratory analysis of retained serum to attempt to tease out more insight on broader inflammatory processes and a deeper analysis of our data against the natural history of the disease with key experts.